Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 7/20 | 0.59 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.47 |
| ▸ | EP300 | Q09472 | 3/20 | 0.46 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.46 |
| ▸ | KAT8 | Q9H7Z6 | 3/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3584443 | 0.86 | GABRA1 (0.56) | IDO1GAAGABRA1GABRB2 | |
| SCHEMBL30537735 | 0.85 | GABRA1 (0.43) | GABRA1GABRB2 | |
| SCHEMBL5682891 | 0.85 | GABRA1 (0.43) | GABRA1GABRB2 | |
| Ammonia Solution, Strong SCHEMBL28878772 | 0.85 | IDO1 (0.41) | IDO1NR3C1PGRNR3C2MEN1 | |
| SCHEMBL27342867 | 0.83 | IDO1 (0.54) | IDO1EP300KAT2BKAT8HDAC3 | |
| SCHEMBL3082795 | 0.82 | IDO1 (0.59) | IDO1EP300KAT2BKAT8HDAC3 | |
| SCHEMBL29357437 | 0.81 | IDO1 (0.65) | IDO1EP300KAT2BKAT8HDAC3 | |
| SCHEMBL1397170 | 0.81 | IDO1 (0.65) | IDO1EP300KAT2BKAT8HDAC3 | |
| SCHEMBL4612497 | 0.81 | IDO1 (0.65) | IDO1EP300KAT2BKAT8HDAC3 | |
| SCHEMBL8963168 | 0.80 | DHFR (0.42) | IDO1MEN1GAAKMT2AGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5182213-A | Coupling a Phenylenediamine and a Naphthol | MILES INC. (US) | 1993-01-26 | — | — | US | claimed |
| EP-0504663-A1 | Peroxidase indicator system for basic media | Bayer Corporation (US) | 1992-09-23 | — | — | EP | claimed |
| EP-4371982-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX Pharmaceuticals, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-3583096-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20230133667-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230133667-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230133667-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2023-05-04 | — | — | US | disclosed |
| CN-110520413-B | Macrocyclic broad spectrum antibiotics | 阿奇克斯制药公司 | 2023-02-17 | — | — | CN | disclosed |
| US-20210198316-A9 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-07-01 | — | — | US | disclosed |
| US-20210198316-A9 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-07-01 | — | — | US | disclosed |
| CN-110520413-A | Big ring broad-spectrum antibiotic | RQX PHARMACEUTICALS INC | 2019-11-29 | — | — | CN | disclosed |
| US-4100205-A | Oxidative coupling of alkylphenols or 1-naphthols catalyzed by metal complexes of aminoketo compounds | ICI AMERICAS INC. (US) | 1978-07-11 | — | — | US | disclosed |
| US-4100206-A | Oxidative coupling of alkylphenols or 1-naphthols catalyzed by metal complexes of keto alcohol compounds | ICI AMERICAS INC. (US) | 1978-07-11 | — | — | US | disclosed |
| US-4098830-A | OXIDATIVE COUPLING OF ALKYLPHENOLS OR 1-NAPHTHOLS CATALYZED BY METAL COMPLEXES OF DICARBOXYLIC ACID COMPOUNDS | ICI AMERICAS INC. (US) | 1978-07-04 | — | — | US | disclosed |
| US-4097461-A | Oxidative coupling of alkylphenols or 1-naphthols catalyzed by metal complexes of diketo compounds | ICI AMERICAS INC. (US) | 1978-06-27 | — | — | US | disclosed |
| US-4096190-A | Oxidative coupling of alkylphenols catalyzed by metal ammonia complexes | ICI AMERICAS INC. (US) | 1978-06-20 | — | — | US | disclosed |
| US-4085124-A | Oxidative coupling of alkylphenols, alkoxyphenols and 1-naphthols catalyzed by metal complexes of amino compounds | ICI AMERICAS INC. (US) | 1978-04-18 | — | — | US | disclosed |
| US-4070383-A | COPPER COMPOUND-ANIONIC SURFACTANT-ALKALI METAL COMPOUND CATALYST SYSTEM | ICI AMERICAS INC. (US) | 1978-01-24 | — | — | US | disclosed |
| US-4067890-A | Oxidative coupling of alkylphenols, alkoxyphenols and naphthols catalyzed by metal complexes of amino carboxylic and amino sulfonic acids | ICI AMERICA INC. (US) | 1978-01-10 | — | — | US | disclosed |
| US-4062904-A | Removal of hydroxyl-, carboxy-, or amino substituents from aromatic compounds using a group VI B catalyst | UOP INC. (US) | 1977-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198316-A9 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | IDO1 2405/4885NR3C1 4663/4885PGR 4065/4885 |
| US-20230133667-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | IDO1 2405/4885NR3C1 4663/4885PGR 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.